Project Grant K38CA304069
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $109K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Rochester provides $639,098 to develop an innovative treatment for metastatic pancreatic cancer. The research aims to overcome both intrinsic and extrinsic barriers to treatment efficacy, specifically by targeting the tumor microenvironment through a combination of local radiotherapy and intratumoral immunotherapy using a novel mRNA-based nanoparticle delivery system. The...
- This $151,263 federal Project Grant award was provided by the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) program to fund a research project titled "Understanding Paracrine Interactions Induced by Morphogens in PDAC" at The Trustees of Columbia University in the City of New York. The project aims to identify how active morphogen signaling shapes local immunosuppression in the pancreatic tumor microenvironment by studying the interactions between malignant...
- This $118,722 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to develop a novel immunotherapy for pancreatic cancer. The grant funding will be used by Emory University to engineer CD4+ T cells expressing high levels of the enzyme CD26 and equip them with a chimeric antigen receptor (CAR) targeting mesothelin, a protein expressed on pancreatic tumor cells. The research aims to harness the favorable properties of CD26+ T cells to...
- The federal Project Grant award of $268,345 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a novel immunotherapy for pancreatic cancer. The primary awardee, Sanford Burnham Prebys Medical Discovery Institute, will investigate the PSGL-1/VISTA axis as a potential target for boosting the anti-tumor immune response in pancreatic tumors. This 2-year project, with a start date of Mar 10, 2025 and end date of Feb 28, 2027, aims to elucidate...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $162,486 to the University of Miami to support research into a novel immunotherapy approach for pancreatic cancer using microRNA-29a. The goal is to determine how microRNA-29a can regulate T cell exhaustion and restore anti-tumor immunity in pancreatic ductal adenocarcinoma (PDAC), which has a very low 5-year survival rate of 12%. The research will utilize the KPC mouse model of PDAC...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to Georgetown University for $109,386 provides funding to investigate strategies to increase the co-localization of activated natural killer (NK) cells with tumor cells in pancreatic ductal adenocarcinoma (PDAC). The research aims to explore how inhibiting dipeptidyl peptidases (DPPs) can enhance the efficacy of anti-PD1 immunotherapy by increasing NK cell infiltration and reducing fibrosis in...
- The National Cancer Institute awarded a $119,858 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Regents of the University of Minnesota, Office of Sponsored Projects Administration. The award supports research to elucidate mechanisms governing immune surveillance and resistance to antitumor T cell response in pancreatic cancer. The project aims to identify ways to safely promote T cell-mediated destruction of pancreatic cancer through combinatorial immunotherapies....
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to support research by Oncotab, Inc. on optimized targeted radiotherapy for pancreatic cancer. The key objectives are to develop a tumor-specific antibody (HTAB004) and a tandem single-chain variable fragment (scFv) targeting agent labeled with alpha and beta particle-emitting radioisotopes. This research aims to overcome the challenge of the desmoplastic stroma in pancreatic...
- This $677,176 federal Project Grant award, funded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports the development of an interstitial chemophototherapy (I-CPT) approach for treating locally advanced pancreatic cancer. The grantee, The Research Foundation For The State University Of New York (RF SUNY), will advance its long-circulating liposomal irinotecan formulation integrated with porphyrin-phospholipid (IRT-POP) for photoablation of large...
- This $640,583 federal Project Grant was awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Cold Spring Harbor Laboratory to conduct research aimed at enhancing the efficacy of immunotherapy against metastatic colorectal cancer. The primary goal is to activate the PPARD-CPT1A axis in CD8+ T cells to boost their anti-tumor immunity and improve treatment outcomes for patients with microsatellite stable metastatic colorectal cancer, who typically respond poorly...